Vanderbilt Ingram Cancer Center
Aug. 24, 2017—Vanderbilt-Ingram Cancer Center (VICC) will host the 2017 Cancer Survivors Celebration Sunday, Sept. 10, from 2–4 p.m. This year’s free event, offered in partnership with Monroe Carell Jr. Children’s Hospital at Vanderbilt, will be held at the Vanderbilt Student Life Center, 310 25th Ave. South.
Aug. 17, 2017—Vanderbilt-Ingram Cancer Center (VICC) will sponsor an educational conference for kidney cancer patients, survivors and family members Saturday, Sept. 9, 8 a.m. – 2 p.m., in the Preston Research Building, Suite 898.
Aug. 17, 2017—A group of nationally recognized medical information and data management experts has recommended the development of new knowledge software applications that work alongside electronic health record systems (EHRs) to help practicing oncologists access and use the latest genomic information to assist in the treatment of cancer patients.
Aug. 15, 2017—Vanderbilt University Medical Center (VUMC) has been named to the Becker’s Hospital Review roster of 100 Hospitals and Health Systems with Great Oncology Programs.
Aug. 10, 2017—In her life, Jessi Zazu, 27, has toured the world as a musician in the group Those Darlins, recorded three studio albums, starred in music videos and exhibited her original artwork in individual and group art shows.
Aug. 9, 2017—Thanks to advances in treatment, the relative five-year survival rate from all combined subtypes of breast cancer now exceeds 90 percent and yet the disease remains the third leading cause of cancer deaths in the United States after lung and colorectal cancers.
Aug. 3, 2017—Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients.
Aug. 3, 2017—The Nashville Sounds baseball team recently highlighted cancer care at Vanderbilt-Ingram Cancer Center (VICC) during a special “Cancer Awareness Night.”
Jul. 20, 2017—Researchers at Vanderbilt University Medical Center (VUMC) have discovered a protein that may lead to a new way to prevent resistance and improve outcomes for patients whose cancers have mutations in the tumor suppressor gene BRCA2.
Jul. 13, 2017—Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies (C2T2), director of the Breast Cancer Research Program and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named director of the Harold C. Simmons Comprehensive Cancer Center and associate dean of Oncology Programs at the UT Southwestern Medical Center in Dallas.